Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14967349 | 0.83 | PPM1B (0.42) | LMNAPOLBALDH1A1PPM1BPTPN1 | |
| SCHEMBL2139493 | 0.81 | LMNA (0.40) | LMNAPOLBALDH1A1PPM1BPTPN1 | |
| SCHEMBL14967555 | 0.79 | ALDH1A1 (0.47) | LMNAPOLBALDH1A1TSHR | |
| SCHEMBL14966710 | 0.78 | SOAT1 (0.39) | LMNAPOLBALDH1A1PPM1BPTPN1 | |
| SCHEMBL14967620 | 0.78 | NAAA (0.46) | LMNAALDH1A1TSHR | |
| SCHEMBL8076664 | 0.77 | LMNA (0.37) | LMNAPOLBALDH1A1PPM1BPTPN1 | |
| SCHEMBL8076662 | 0.77 | LMNA (0.37) | LMNAPOLBALDH1A1PPM1BPTPN1 | |
| SCHEMBL14967677 | 0.77 | NAAA (0.48) | LMNAALDH1A1TSHR | |
| SCHEMBL13422928 | 0.76 | TSHR (0.44) | LMNAALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2749084 | 0.76 | TSHR (0.44) | LMNAALDH1A1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458270-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2016-10-04 | — | — | US | claimed |
| EP-2780177-B1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORP (JP) | 2016-03-23 | — | — | EP | claimed |
| US-20140296445-A1 | Method For Producing Polydienes And Polydiene Copolymers With Reduced Cold Flow | BRIDGESTONE CORPORATION (JP) | 2014-10-02 | — | — | US | claimed |
| EP-2780177-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | Bridgestone Corporation (JP) | 2014-09-24 | — | — | EP | claimed |
| WO-2013075074-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2013-05-23 | — | — | WO | claimed |
| US-20240383870-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| EP-4362930-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | Aldeyra Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117580569-A | Heterocyclic aldehyde capture compounds and uses thereof | 奥尔德拉医疗公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023278816-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-10301397-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20160340447-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| US-5387575-A | Pyrimidine derivatives, process for preparing the same and herbicide using the same | UBE INDUSTRIES, LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| US-5178663-A | Pyrimidinyloxy or pyrimidinylthio compounds | UBE INDUSTRIES, LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| CN-1067651-A | Pyrimidine or triazine derivative, their preparation method and use them as weedicide | UBE INDUSTRIES (JP) | 1993-01-06 | — | — | CN | disclosed |
| EP-0517215-A1 | Pyrimidine or triazine derivative, process for preparing the same and herbicide using the same | UBE INDUSTRIES, LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
| EP-0153692-B1 | METHOD FOR ISOMERIZATION A GLYCIDATE DERIVATIVE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-07-29 | — | — | EP | disclosed |
| EP-0481512-A1 | 3-Alkoxyalkanoic acid derivative, process for preparing the same and herbicide using the same | UBE INDUSTRIES, LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
| US-4621150-A | METAL PERHALATE OR SULFONATE OR COMPLEX; GLYCIDATE, 2-HYDROXY-3-BUTENOATE, EPOXIDE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-11-04 | — | — | US | disclosed |
| EP-0153692-A2 | Method for isomerization a glycidate derivative | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383870-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDH1A2, ALDH2, SSB | LMNA 2267/4885POLB 4081/4885ALDH1A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.